Daniel Savignon Marinho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Savignon Marinho has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bruno LA Ferreira
LABioMol, Instituto de Biologia, UFF, Niterói, RJ, Brazil
1 shared publication - Carlos Rangel Rodrigues
Molecular Modeling and 3D-QSAR Laboratory, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, RJ, Brazil
1 shared publication - Gisele Huf
Fundação Oswaldo Cruz
1 shared publication - Helena Carla Castro
Universidade Federal Fluminense, Hospital Universitário Antônio Pedro, Programa de Pós-graduação em Patologia, 24033-900 Niterói, RJ, Brazil; Universidade Federal Fluminense, Instituto de Biologia, Programa de Pós-graduação em Ciências e Biotecnologia, CEP 24210-130, Niterói, RJ, Brazil
1 shared publication - Lucio Mendes Cabral
Universidade Federal do Rio de Janeiro
1 shared publication - Valeria Pereira de Sousa
Laboratory for Drug and Medicine Quality Control (LabCQ), Department of Drugs and Pharmaceutics, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- Open Access
- 15 July 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 236
The study of vancomycin use and its adverse reactions associated to patients of a brazilian university hospital
Vancomycin is an antibiotic of growing importance in the treatment of hospital infections, with particular emphasis on its value in the fight against methicillin-resistant Staphylococcus aureus. However its usage profile must be evaluated to assure maximum benefit and minimum risk.
- 15 July 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 236
Open AccessThe study of vancomycin use and its adverse reactions associated to patients of a brazilian university hospital
Vancomycin is an antibiotic of growing importance in the treatment of hospital infections, with particular emphasis on its value in the fight against methicillin-resistant Staphylococcus aureus. However its usage profile must be evaluated to assure maximum benefit and minimum risk.